Agenda for the NNBCR kick-off meeting in Gothenburg

Monday 21/9

 

09.20-09.40                     Gathering and “Fika” at Arvid Carlsson salen, Medicinareg. 3

 

Session 1,                        Chairs: Tommy Martinsson and Bengt Hallberg

Talks are 15 min., + 5 min discussion

 

09.50-10.00,                    Tommy Martinsson welcomes us and summarizes NNBCR, goals and targets

 

10.00-10.10,                    Presentations of participants

 

10.10-10.30,             NGS in neuroblastoma – The Gothenburg experience.

Susanne Fransson (group TM)

 

10.30-10.50,                    Inhibition of Rho kinase represses neuroblastoma growth by inducing differentiation and MYCN degradation.

Malin Wickström (JIJ)

 

10.50-11.10,                    Analysis of somatic structural alterations and their influence on gene expression in diverse human cancers.

Babak Alaei-Mahabad (EL)

 

11.10-11.30,                    The PPM1D encoded WIP1 phosphatase is a novel oncogene and potential therapeutic target in neuroblastoma and medulloblastoma.

Jelena Milosevic (PK)

 

11.30-11.50,             6p22 lncRNAs and neuroblastoma.

Tanmoy Mondal, (CK)

 

11.50-12.10,             CNK, a downstream target of ALK.

Georg Wolfstetter (RP)

 

 

12.10-13.30                     Lunch at “Lyktan”

 

 

 

Session 2,                        Chairs: Erik Lekholm and Chandrasekhar Kanduri

 

13.30-13.50,             PF-06463922 is a superior drug in a NB setting.

Jikui Guan (BH)

 

13.50-14.10,             ALK gene mutation in Neuroblastoma.

Niloufar Javanmardi (TM)

 

14.10-14.30,                    COX/mPGES- 1/PGE2 pathway depicts an inflammatory dependent high-risk neuroblastoma subset available for novel specific anti-inflammatory treatment.

Anna Kock (PK)

 

14.30-14.50,             Negative selection during tumor evolution.

Jimmy van den Eynden (EL)

 

 

14.50-15.10                     Coffee   

 

 

Session 3,                        Chairs: Per Kogner and Ruth Palmer

 

15.10-15.30,                    Targeting suppressive myeloid cells in neuroblastoma augments checkpoint blockade therapy.

Nina Eissler (JIJ)

 

15.30-15.50,                    Characterization of potential tumor suppressor on chromosome 17.

Kankadeb Mishra (CK)

 

15.50-16.10,             AP-26113, a player on the neuroblastoma field.

Joachim Siaw (BH)

 

16.10-16.30,            A Fam-tastic activator of ALK.

Ruth Palmer (RP)

 

16.30-16.50,             Discussions and Conclusions

 

 

Check in HOTEL             Clarion Hotel Post, Drottningtorget 10

 

 

19.00-                                Dinner at restaurant “El Corazon”, Kungstorget

 

Tuesday 22/9

 

Departure at own time.

 

 

09.00-13.00                     NNBCR PI meeting,

at Stina Stenhagen conf. room, Medicinaregatan 3,

 

First discussion regarding 12th of November, 2015 and future planning. Tommy will lead this

 

10.00                                 Coffee

 

 

12-ish                                Lunch at Lyktan – the end.